



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Barrow, et al.	
Serial No.:	10/582,856	Case No.: 21592YP
US Nat'l Filing Date:	June 14, 2006	
For:	PHENYLAMIDE AND PRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

Examiner:
Davis, Zinna
Northington

Group Art
Unit: 1625

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.97

Sir:

In compliance with 37 CFR §1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

BY: Nancy Reynolds DATE: 5/19/08

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b). In accordance with 37 CFR §1.97 (g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


References on the accompanying PTO 1449 form were cited in the Search Report for the EPO counterpart of this application (EPO Appln. No. 04 814 367.1). A copy of the EPO Communication is included with the Information Disclosure Statement.

Pursuant to 37 CFR §1.97(b)(3), this Information Disclosure Statement is being mailed more than three months after the filing date of the present application but before the mailing date of a first office action. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



John C. Todaro, Reg. No. 36,036
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065
Tel.: (732) 594-0125

Date: May 19, 2008